Roundup crop science lawyers allege the chemical manufacturer Bayer is liable for non-hodgkin lymphoma cancer caused by their product.
Roundup Crop Science Drives Corporate Growth and Lawsuits
Nevertheless, Bayer has reported a continued demand for its weed killer product. To wit, Bayer’s stock has performed well despite the rising number of Roundup crop science lawsuits pending against the company.
Bayer’s stock increased 3.8% in the early days of the global COVID-19 outbreak. This valuation increase cut the company’s annual losses to 15%.
Click here to view the latest Bayer stock quote.
Despite the improved financial position, Bayer opted to delay negotiating a settlement with Roundup crop science lawyers. This strategic decision may be an attempt to leverage economic factors in its favor.
Click here for additional information on our Roundup cancer lawyers.
Roundup Crop Science Lawyers Navigate COVID-19 Economics
Both in the United States and globally, Coronavirus infections continue to plague the public. As a result, Roundup crop science lawsuits have experienced a slowdown in the resolution process.
This has occurred while Bayer’s stock price increased on the Euro Stoxx 50 Index by 1.9%, consistent with emergence from the initial COVID-19 lockdown.
Such increases follow quarterly earnings and sales that exceed analyst expectations. Moreover, the stock price up-ticks appear attributed to a rise in demand for Roundup crop science products.
Pesticide Scientists Elevate Bayer Earning Estimates
Roundup crop science lawsuit settlement negotiations have slowed in spite of Bayer maintaining a positive financial outlook.
Despite the effects of the COVID-19 lockdown, Bayer announced targeted annual earnings estimates at or slightly above 7 euros per share of stock.
This news followed businesses and residential consumers purchasing and stockpiling supplies in advance of the Coronavirus pandemic.
